Clinical data | |
---|---|
Trade names | Prosom, Esilgan, Eurodin, Nuctalon, others |
Other names | Desmethylalprazolam |
AHFS/Drugs.com | Monograph |
MedlinePlus | a691003 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 93% |
Metabolism | Liver |
Elimination half-life | 10–24 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.045.424 |
Chemical and physical data | |
Formula | C16H11ClN4 |
Molar mass | 294.74 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Estazolam, sold under the brand name Prosom among others, is a tranquilizer medication of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. Estazolam is an intermediate-acting oral benzodiazepine. It is used for short-term treatment of insomnia.
It was patented in 1968 and came into medical use in 1975.[5]
Estazolam FDA label
was invoked but never defined (see the help page).